WuXi Biologics (Cayman) Inc.

28 days ago · seekingalpha.com

WuXi Biologics (Cayman) Inc. (WXXWY) Q2 2026 Earnings Call Transcript

1 month ago · defenseworld.net

WuXi Biologics (Cayman) Inc. (OTCMKTS:WXXWY - Get Free Report) was the recipient of a significant drop in short interest during the month of July. As of July 31st, there was short interest totaling 46,353 shares, a drop of 81.8% from the July 15th total of 255,103 shares. Based on an average daily volume of 113,253

3 months ago · prnewswire.com

SHANGHAI, June 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG17 drug substance facility located at the Shanghai Fengxian site has successfully completed its first GMP production campaign. The manufacturing process execution was completed with zero deviations, while critical process parameters remained stable and yields reached expected levels, demonstrating robust process performance and strong execution capabilities.

3 months ago · prnewswire.com

SUZHOU, China, June 18, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its Biosafety Testing Center in Suzhou has successfully passed a Good Manufacturing Practice (GMP) inspection by the European Medicines Agency (EMA) with zero critical findings. This marks the fourth time the facility has successfully received EMA GMP certificate.